Cardiac Biomarkers
Cardiac Biomarkers - Related Videos
09:23
Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
0 Views •
Cited by 2 •
2017
This work describes a nanoimprinting lithography method to fabricate high-quality sensing arrays that work on the principle of extraordinary optical transmission. The biosensor is low-cost, robust, easy to use, and can detect cardiac troponin I in serum at clinically relevant concentrations (99th percentile cutoff ∼10-400 pg/mL, depending on the assay).
01:20
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
0 Views •
2025
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging. The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include: Troponins Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
08:29
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
0 Views •
Cited by 29 •
2012
We describe a rat model of post traumatic stress disorder (PTSD) that reveals the persistent alterations in neuroendocrine function and the delayed long-term, exaggerated fear response, characteristic of PTSD patients. The animal model and methods described here are useful for correlating biomarkers in brain nuclei, which are mechanistic but cannot be measured in patients, with biomarkers in peripheral white blood cells, which can.
08:28
An Overview of bGDGT Biomarker Analysis for Paleoclimatology
0 Views •
2023
Source: Laboratory of Jeff Salacup - University of Massachusetts Amherst Throughout this series of videos, natural samples were extracted and purified in search of organic compounds, called biomarkers, that can relate information on climates and environments of the past. One of the samples analyzed was sediment. Sediments accumulate over geologic time in basins, depressions in the Earth into which sediment flows through the action of fluid (water or air), movement, and gravity. Two main types...
08:25
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
0 Views •
Cited by 11 •
2015
Streptococcus pneumoniae forms discrete non-purulent microscopic lesions in the heart. Outlined is the protocol for a murine model of cardiac microlesion formation. Instruction is provided on microlesion visualization using microscopy, discrimination between early and late microlesions, and methods to detect cardiac remodeling in hearts of convalescent animals.
FAQs
Different cardiac stresses produce different biomarker signals. Myocardial ischemia can prompt cardiac cells to release troponin proteins, whereas increased ventricular wall tension is associated with natriuretic peptide release. This distinction gives clinicians complementary information: troponins support assessment of myocardial injury, while natriuretic peptides reflect hemodynamic stress relevant to heart failure.
Cardiac troponins and natriuretic peptides answer different clinical questions. Troponin results are central when clinicians evaluate suspected acute myocardial infarction, whereas natriuretic peptide results help assess heart failure and hemodynamic stress. Using the appropriate marker for the suspected problem prevents a single laboratory value from being treated as a universal indicator of cardiac disease.
Changing concentrations add information that a single measurement cannot provide. Clinicians consider whether levels rise or fall while assessing symptoms, examination findings, and electrocardiography. This time-related pattern helps place a biomarker result within the suspected clinical event and supports more informed diagnostic assessment than an isolated concentration alone.
An elevated biomarker does not by itself establish primary coronary injury. Cardiac biomarker concentrations must be interpreted in clinical context because abnormalities can occur in conditions other than primary coronary injury. Symptoms, physical examination, electrocardiography, and the pattern of changing levels help clinicians judge what the result means.
Clinical use combines a blood result with the patient’s presentation rather than relying on laboratory data alone. Clinicians assess symptoms, examination findings, electrocardiography, and biomarker concentrations or trends together. This integrated approach supports timely assessment and helps distinguish evidence requiring further evaluation from a result whose significance remains uncertain.
These tests can influence several stages of care. Troponin findings support diagnostic assessment of suspected acute myocardial infarction, while natriuretic peptide findings contribute to heart-failure assessment. Biomarker information also supports risk stratification, treatment decisions, and monitoring, making it useful beyond initial diagnosis when interpreted with the broader clinical picture.